Background
Methods
Case selection
Variable | n | % |
---|---|---|
Age
| ||
>51 |
48
| 56.5 |
≤51 |
37
| 43.5 |
Gender
| ||
Female |
33
| 38.8 |
Male |
52
| 61.2 |
Race
| ||
Caucasian |
63
| 74.1 |
Not Caucasian |
22
| 25.9 |
Local
| ||
Lower extremities |
63
| 73.3 |
Upper extremities |
23
| 26.7 |
Diagnostic
| ||
Pleomorphic leiomyosarcoma |
17
| 19.8 |
Myxoid/round cells liposarcoma |
14
| 16.3 |
High grade undifferentiated pleomorphic sarcoma |
12
| 14.0 |
Monophasic fibrous synovial sarcoma |
9
| 10.5 |
Myxofibrosarcoma |
7
| 8.1 |
Malignant peripheral nerve sheath tumor |
7
| 8.1 |
Low grade fibromyxoid sarcoma |
3
| 3.5 |
Poorly differentiated synovial sarcoma |
2
| 2.3 |
High grade myofibroblastic sarcoma |
2
| 2.3 |
Clear cell sarcoma |
1
| 1.2 |
Biphasic synovial sarcoma |
1
| 1.2 |
Fibrosarcoma |
1
| 1.2 |
Angiomatoid histiocytoma |
1
| 1.2 |
Infantile fibrosarcoma |
1
| 1.2 |
Well differentiated liposarcoma |
1
| 1.2 |
Undifferentiated liposarcoma |
1
| 1.2 |
Pleomorphic liposarcoma |
1
| 1.2 |
Acral myxoinflammatory fibroblastic sarcoma |
1
| 1.2 |
Low grade myofibroblastic sarcoma |
1
| 1.2 |
Giant-cell-rich high grade undifferentiated pleomorphic sarcoma |
1
| 1.2 |
Malignant solitary fibrous tumor |
1
| 1.2 |
Alveolar sarcoma |
1
| 1.2 |
Cell lineage
| ||
Fibroblastic/myofibroblastic |
28
| 32.5 |
Smooth muscle |
17
| 19.8 |
Lipogenic |
17
| 19.8 |
Peripheral nerve |
7
| 8.1 |
Miscellaneous |
17
| 19.8 |
Cellular pleomorphism
| ||
Absence of pleomorphic cells |
54
| 62.8 |
Presence of pleomorphic cells |
32
| 37.2 |
Grade
| ||
Low grade (I) |
30
| 32.2 |
High grade (II e III) |
63
| 67.7 |
Disease progression
| ||
No |
25
| 30.9 |
Yes |
56
| 69.1 |
Disease recurrence
| ||
Absent |
48
| 57.1 |
Present |
36
| 42.9 |
Metastasis
| ||
Absent |
44
| 52.4 |
Present |
40
| 47.6 |
Immunohistochemistry
MCT and CD147 detection
Immunohistochemical evaluation
Immunofluorescence
Cell fractionation and Western blot
Statistical analysis
Results
Soft tissue sarcomas show nuclear expression of MCT1
n | CD147 positive (%) |
p
| |
---|---|---|---|
MCT1
|
<0.001
| ||
Negative |
34
| 3 (8.8) | |
Positive |
52
| 36 (67.3) | |
MCT4
|
0.005
| ||
Negative |
37
| 10 (27.0) | |
Positive |
49
| 29 (57.1) |
Plasma membrane expression of MCT1 and MCT4 is associated with poor prognostic features, while nuclear expression of MCT1 is associated with good prognosis
Clinical-pathological data
|
MCT1 (PM)
|
MCT1 (nucleus)
|
MCT4 (PM)
| ||||
---|---|---|---|---|---|---|---|
n | Positive (%) |
p
| Positive (%) |
p
| Positive (%) |
p
| |
Age
| 0.153 | 0.076 | 0.403 | ||||
>51 |
48
| 32 (66.7) | 12 (25.0) | 29 (60.4) | |||
≤51 |
37
| 19 (51.4) | 16 (43.2) | 19 (51.4) | |||
Gender
| 0.716 | 0.174 | 0.463 | ||||
Female |
33
| 19 (57.6) | 8 (24.2) | 17 (51.5) | |||
Male |
52
| 32 (61.5) | 20 (38.5) | 31 (59.6) | |||
Race
| 0.686 | 0.896 | 0.832 | ||||
Caucasian |
63
| 37 (58.7) | 21 (33.3) | 36 (57.1) | |||
Not Caucasian |
22
| 14 (63.6) | 7 (31.8) | 12 (54.5) | |||
Local
| 0.586 | 0.439 | 0.154 | ||||
Lower extremities |
63
| 37 (58.7) | 22 (34.9) | 33 (52.4) | |||
Upper extremities |
23
| 15 (65.2) | 6 (26.1) | 16 (69.6) | |||
Cell lineage
| 0.066 |
<0.001
|
<0.001
| ||||
Fibroblastic/myofibroblastic |
28
| 16 (57.1) | 9 (32.1) | 16 (57.1) | |||
Smooth muscle |
17
| 12 (70.6) | 3 (17.6) | 13 (76.5) | |||
Lipogenic |
17
| 6 (35.3) | 13 (76.5) | 2 (11.8) | |||
Peripheral nerve |
7
| 4 (57.1) | 2 (28.6) | 4 (57.1) | |||
Miscellaneous |
17
| 14 (82.4) | 1 (5.9) | 14 (82.4) | |||
Cellular pleomorphism
|
0.034
|
0.010
|
0.009
| ||||
Absence of pleomorphic cells |
54
| 28 (51.9) | 23 (42.6) | 25 (46.3) | |||
Presence of pleomorphic cells |
32
| 24 (75.0) | 5 (15.6) | 24 (75.0) | |||
Grade
|
<0.001
|
<0.001
|
0.011
| ||||
Low grade (I) |
19
| 4 (21.1) | 14 (73.7) | 6 (31.6) | |||
High grade (II e III) |
67
| 48 (71.6) | 14 (20.9) | 43 (64.2) | |||
Disease progression
|
0.018
| 0.865 | 0.060 | ||||
No |
25
| 10 (40.0) | 8 (32.0) | 10 (40.0) | |||
Yes |
56
| 39 (67.2) | 20 (33.9) | 35 (62.5) | |||
Disease recurrence
| 0.847 | 0.640 | 0.204 | ||||
Absent |
48
| 29 (60.4) | 15 (31.2) | 24 (50.0) | |||
Present |
36
| 21 (58.3) | 13 (36.1) | 23 (63.9) | |||
Metastasis
| 0.156 | 0.122 | 0.249 | ||||
Absent |
44
| 23 (52.3) | 18 (40.9) | 22 (50.0) | |||
Present |
40
| 27 (67.5) | 10 (25.0) | 25 (62.5) |
Clinical-pathological data
|
CD147
|
CD147 + MCT1
|
CD147 + MCT4
| ||||
---|---|---|---|---|---|---|---|
n | Positive (%) |
p
| Positive (%) |
p
| Positive (%) |
p
| |
Age
| 0.498 | 0.583 | 0.308 | ||||
>51 |
48
| 23 (47.9) | 21 (43.8) | 18 (37.5) | |||
≤51 |
37
| 15 (40.5) | 14 (37.8) | 10 (27.0) | |||
Gender
| 0.577 | 0.523 | 0.680 | ||||
Female |
33
| 16 (48.5) | 15 (45.5) | 10 (30.3) | |||
Male |
52
| 22 (42.3) | 29 (38.5) | 19 (34.6) | |||
Race
| 0.562 | 0.976 | 0.511 | ||||
Caucasian |
63
| 27 (42.9) | 26 (41.3) | 22 (34.9) | |||
Not Caucasian |
22
| 11 (50.0) | 9 (40.9) | 6 (27.3) | |||
Local
| 0.936 | 0.751 | 0.432 | ||||
Lower extremities |
63
| 28 (44.4) | 25 (39.7) | 19 (30.2) | |||
Upper extremities |
23
| 10 (43.5) | 10 (43.5) | 9 (39.1) | |||
Cell lineage
| 0.878 | 0.694 | 0.071 | ||||
Fibroblastic/myofibroblastic |
28
| 13 (46.4) | 12 (42.9) | 12 (42.9) | |||
Smooth muscle |
17
| 6 (35.3) | 6 (35.3) | 5 (29.4) | |||
Lipogenic |
17
| 7 (41.2) | 5 (29.4) | 1 (5.9) | |||
Peripheral nerve |
7
| 3 (42.9) | 3 (42.9) | 2 (28.6) | |||
Miscellaneous |
17
| 9 (52.9) | 9 (52.9) | 8 (47.1) | |||
Cellular pleomorphism
| 0.083 | 0.071 |
0.002
| ||||
Absence of pleomorphic cells |
54
| 20 (37.0) | 18 (33.3) | 11 (20.4) | |||
Presence of pleomorphic cells |
32
| 18 (56.2) | 17 (53.1) | 17 (53.1) | |||
Grade
| 0.076 |
0.016
|
0.026
| ||||
Low grade (I) |
19
| 5 (26.3) | 3 (15.8) | 2 (10.5) | |||
High grade (II e III) |
67
| 33 (49.3) | 32 (47.8) | 26 (38.8) | |||
Disease progression
|
0.020
|
0.016
| 0.070 | ||||
No |
25
| 6 (24.0) | 5 (20.0) | 4 (16.0) | |||
Yes |
56
| 29 (51.8) | 27 (48.2) | 21 (37.5) | |||
Disease recurrence
| 0.949 | 0.847 | 0.840 | ||||
Absent |
48
| 21 (43.8) | 19 (39.6) | 15 (31.2) | |||
Present |
36
| 16 (44.4) | 15 (41.7) | 12 (33.3) | |||
Metastasis
| 0.295 | 0.090 | 0.593 | ||||
Absent |
44
| 17 (38.6) | 14 (31.8) | 13 (29.5) | |||
Present |
40
| 20 (50.0) | 20 (50.0) | 14 (35.0) |